dc.contributor.author | Bota, Patrícia | |
dc.contributor.author | Thambiraj, Geerthy | |
dc.contributor.author | Bollepalli, Sandeep C. | |
dc.contributor.author | Armoundas, Antonis A. | |
dc.date.accessioned | 2025-05-16T13:35:38Z | |
dc.date.available | 2025-05-16T13:35:38Z | |
dc.date.issued | 2024-10-29 | |
dc.identifier.uri | https://hdl.handle.net/1721.1/159284 | |
dc.description.abstract | Purpose of Review This opinion paper highlights the advancements in artificial intelligence (AI) technology for cardiovascular disease (CVD), presents best practices and transformative impacts, and addresses current concerns that must be resolved for broader adoption. Recent Findings With the evolution of digitization in data collection, large amounts of data have become available, surpassing the human capacity for processing and analysis, thus enabling the application of AI. These models can learn complex spatial and temporal patterns from large amounts of data, providing patient-specific outputs. These advantages have resulted, at the moment, in more than 900 AI-based devices being approved, today, by regulatory entities, for clinical use, with similar to improved performance and efficiency compared to traditional technologies. However, issues such as model generalization, bias, transparency, interpretability, accountability, and data privacy remain significant barriers for broad adoption of these technologies. Summary AI shows great promise in enhancing CVD care through more accurate and efficient approaches. Yet, widespread adoption is hindered by unresolved concerns of interested stakeholders. Addressing these challenges is crucial for fully integrating AI into clinical practice and shaping the future of CVD prevention, diagnosis and treatment. | en_US |
dc.publisher | Springer US | en_US |
dc.relation.isversionof | https://doi.org/10.1007/s11886-024-02146-y | en_US |
dc.rights | Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. | en_US |
dc.source | Springer US | en_US |
dc.title | Artificial Intelligence Algorithms in Cardiovascular Medicine: An Attainable Promise to Improve Patient Outcomes or an Inaccessible Investment? | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Bota, P., Thambiraj, G., Bollepalli, S.C. et al. Artificial Intelligence Algorithms in Cardiovascular Medicine: An Attainable Promise to Improve Patient Outcomes or an Inaccessible Investment?. Curr Cardiol Rep 26, 1477–1485 (2024). | en_US |
dc.contributor.department | Broad Institute of MIT and Harvard | en_US |
dc.relation.journal | Current Cardiology Reports | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dc.date.updated | 2025-03-27T13:49:23Z | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature | |
dspace.embargo.terms | Y | |
dspace.date.submission | 2025-03-27T13:49:23Z | |
mit.journal.volume | 26 | en_US |
mit.license | PUBLISHER_POLICY | |
mit.metadata.status | Authority Work and Publication Information Needed | en_US |